Background And Aim: Infliximab (IFX) has revolutionized the treatment of patients with Crohn's disease (CD). However, a significant proportion of patients may fail to respond primarily or lose response over time. The genetic background of a particular individual may partially explain differences in responsiveness to anti-TNFα therapy. The aim of this study was to investigate whether polymorphisms in the promoter region of the and gene are associated with response to IFX in patients with CD.
Methods: We investigated the following single nucleotide polymorphisms in the promoter region of the gene (-238 G/A, -308 G/A, and -857 C/T) and the -158 V/F polymorphism in the gene in a cohort of 79 adults and 27 children, who were all Greek patients with CD. These polymorphisms were determined using PCR-RFLP or allele-specific PCR.
Results: Regarding the 106 patients included in the study, 68 (64.15%) were classified as complete and 25 (23.58%) as partial responders to IFX, while 13 (12.26%) patients were primary non responders. There were no significant differences in the frequencies of the various and genotypes among complete, partial responders or primary non responders.
Conclusion: These results suggest that and genotypes did not affect the response to IFX in this cohort of Greek patients with CD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959457 | PMC |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive review of paratuberculosis in animals and its implications for public health.
Open Vet J
November 2024
Research Center for Veterinary Science, National Research and Innovation Agency (BRIN), Bogor, Indonesia.
Paratuberculosis is an infectious disease caused by subspecies (MAP). Typically, ruminant animals including cattle, buffalo, goats, and sheep are infected with MAP. Animals get infected with MAP in a number of ways, such as by eating or drinking contaminated food or water, or by nursing from an infected mother who may have contaminated teats or directly shed the organism in milk or colostrum.
View Article and Find Full Text PDF25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024.
Iran Biomed J
December 2024
Student Research Committee, Najafabad Branch, Islamic Azad University, Najafabad, Iran.
Clinical usefulness of patient-reported-outcome-measurement information system in Pediatric Crohn's Disease: a cross-sectional study.
Health Qual Life Outcomes
December 2024
Gastroenterology Unit, Pediatric Department, Santa Maria University Hospital - CHLN, Academic Medical Centre of Lisbon, Lisbon, Portugal.
Objectives: This study evaluated the clinical utility of the Patient-Reported Outcomes Measurement Information System (PROMIS) by comparing it with objective clinical data and validated health-related quality of life (HRQOL) measures in pediatric Crohn's disease (CD) patients.
Study Design: Cross-sectional study. Pediatric CD patients (aged 8-17 years) were enrolled prospectively over eight months from an outpatient pediatric gastroenterology center.
Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.
BMC Gastroenterol
December 2024
Formerly Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic de Barcelona, Barcelona, Spain.
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFHealth-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study.
BMC Gastroenterol
December 2024
Department of Inflammatory Bowel Disease, St Mark's National Bowel Hospital, Central Middlesex Hospital, Acton Lane, London, NW10 7NS, UK.
Background: With 20-40% of patients who have inflammatory bowel disease (IBD) not responding to therapy, resource use and costs can be high. We performed a descriptive analysis of health-care data for IBD management in the National Health Service to explore potential areas for improvement.
Methods: In this exploratory study, we analysed real-world data from the Discover dataset for adults with a diagnosis of incident IBD recorded in northwest London, UK, between 31 March, 2016, and 31 March, 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!